Last reviewed 2026-04-22 · How we verify

VTAMA®

VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis.

VTAMA is a topical retinoid that binds to and activates retinoid X receptors (RXR) to promote skin cell differentiation and reduce inflammation in psoriasis. Used for Plaque psoriasis.

At a glance

Mechanism of action

VTAMA (tapinarof) is a selective retinoid X receptor (RXR) agonist applied topically to affected skin. By activating RXR, it modulates gene expression involved in keratinocyte differentiation and immune regulation, reducing the hyperproliferation and inflammatory cascade characteristic of psoriasis plaques.

Approved indications

• Plaque psoriasis

Common side effects

• Application site irritation
• Erythema
• Pruritus

Key clinical trials

• Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis (PHASE3)
• A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region (PHASE4)
• A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis (PHASE4)
• Vtama in Psoriasis Patients Being Treated With Biologics. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• VTAMA® CI brief — competitive landscape report
• VTAMA® updates RSS · CI watch RSS
• Teva Pharmaceuticals USA portfolio CI